This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Can CVS Health (CVS) Pull a Surprise this Earnings Season?
by Zacks Equity Research
CVS Health (CVS) is poised to gain on strong Pharmacy Services numbers that benefited from the upside in Specialty Pharmacy in Q2.
Why Earnings Season Could Be Great for Teleflex Incorporated (TFX)
by Zacks Equity Research
Teleflex Incorporated (TFX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
MedTech Stocks to Top Q2 Estimates
by Zacks Equity Research
Most of the MedTech majors are lined up to report their earnings results over the next week.
What's in the Cards for DaVita (DVA) this Earnings Season?
by Zacks Equity Research
Despite a stable Kidney Care business, escalating expenses is likely to mar DaVita's (DVA) performance in the second quarter.
Boston Scientific (BSX) Q2 Earnings: What Awaits the Stock?
by Zacks Equity Research
Lower TAVR sales due to recall of Lotus valves within the European and other key markets is likely to mar Boston Scientific's (BSX) top-line performance in Q2.
LabCorp (LH) Q2 Earnings: Is Disappointment in the Cards?
by Zacks Equity Research
With the Covance Drug Diagnostic arm's revenue and margins projected to decline further, LabCorp???s business in Q2 might face disruption.
What's in Store for athenahealth (ATHN) in Q2 Earnings?
by Zacks Equity Research
athenahealth Inc. (ATHN) is set to report second-quarter 2017 results on Jul 20.
Will Intuitive Surgical (ISRG) Surprise in Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical Inc. (ISRG) is scheduled to report second-quarter 2017 results after the closing bell on Jul 20.
Will Thermo Fisher's (TMO) Q2 Earnings Surpass Expectations?
by Zacks Equity Research
Strong focus on product launch and emerging market expansion should drive Thermo Fisher (TMO) toward an earnings beat in Q2.
Can Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report second-quarter 2017 results before the opening bell on Jul 20.
Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical
Teleflex to Introduce Arrow AC3 Optimus at EuroPCR, Paris
by Zacks Equity Research
Teleflex Inc. (TFX) announced plans to introduce Arrow AC3 Optimus Intra-Aortic Balloon Pump at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) in Paris during May 16--19.
Medical Product Stocks' Earnings Due on May 4: ABMD & More
by Zacks Equity Research
Here we discuss four major Medical Product bigwigs, which are scheduled to release their earnings results on May 4.
Invest in These Top 4 GARP Stocks Now
by Zacks Equity Research
The GARP approach prefers stocks that are priced below the market or any reasonable target determined by fundamental analysis.
After ISRG Q1 Earnings, 3 Medical Instrument Stocks Looking Up
by Zacks Equity Research
While the Medical Instrument industry has been oscillating between hope and despair, let us take a look at three stocks which are expected to put up an impressive show this earnings season like Intuitive Surgical.
Teleflex (TFX) Acquires Medical Device Provider Pyng Medical
by Zacks Equity Research
Teleflex Inc. (TFX), a global provider of medical technologies, announced that it has acquired Pyng Medical Corporation.
Moving Average Crossover Alert: Teleflex (TFX)
by Zacks Equity Research
Teleflex (TFX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Teleflex (TFX) Gains FDA Approval for TrapLiner Catheter
by Zacks Equity Research
Teleflex Incorporated (TFX) recently announced 510(k) clearance for its TrapLiner Catheter from the US FDA for a full fledged commercial launch in the country.
MedTech Stocks' Earnings Due on Feb 23: TFX, SAUHF, BIO, PDCO
by Zacks Equity Research
Let's take a look at the major MedTech stocks slated to release their Oct-Dec 2016 numbers on Feb 23.
Teleflex Launches LMA Gastro Airway, FDA Okays Arrow VPS
by Zacks Equity Research
Teleflex Inc. (TFX) recently announced the launch of LMA Gastro Airway with Cuff Pilot Technology and the receipt of 510(k) approval from the U.S. FDA for its Arrow VPS Rhythm device.
Company News for December 05, 2016
by Zacks Equity Research
Companies in the News are: BIG,VASC,TFX,P,SIRI,SBUX